InsiderSignal.AI

InsiderSignal.ai

XNCR - Xencor Inc

Insider Sale by Dahiyat Bassil I (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Dahiyat Bassil I, serving as Pres, CEO at Xencor Inc (XNCR), sold 6,758 shares at $11.90 per share, for a total transaction value of $80,387.00. Following this transaction, Dahiyat Bassil I now holds 567,792 shares of XNCR.

This sale represents a 1.00% decrease in Dahiyat Bassil I's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, March 3, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 4, 2026, 1 day after the trade was made.

Xencor Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Dahiyat Bassil I

Pres, CEO

Bassil Dahiyat, Ph.D. is the President and Chief Executive Officer of Xencor, Inc. (NASDAQ: XNCR), a position he has held since co-founding the company in August 1997.[[1]](https://www.biocom.org/people/bassil-dahiyat-phd/)[[3]](https://xencor.com/about-us/) He is the co-inventor of Xencor’s proprietary XmAb® protein engineering platform, which modifies the Fc domain of antibodies to enhance therapeutic performance, leading to a diverse pipeline of over 20 clinical-stage programs for cancer, autoimmune diseases, and infectious disorders, including three marketed drugs through partnerships with companies like Alexion, Incyte, and Amgen.[[1]](https://www.biocom.org/people/bassil-dahiyat-phd/)[[3]](https://xencor.com/about-us/) Dahiyat holds a Ph.D. in chemistry from the California Institute of Technology (Caltech) and B.S. and M.S.E. degrees in biomedical engineering from Johns Hopkins University.[[1]](https://www.biocom.org/people/bassil-dahiyat-phd/)[[4]](https://virtual.venue-av.com/e/Accelerating_Bio-Innovation/Bassil_Dahiyat_Speaker) His career highlights include authoring numerous scientific papers on protein design and drug delivery, inventing over 30 U.S. patents, and receiving awards from the American Chemical Society, Controlled Release Society, Protein Society, and Caltech.[[1]](https://www.biocom.org/people/bassil-dahiyat-phd/) He serves on the boards of Kodiak Sciences and Terray Therapeutics and has navigated Xencor through challenges, including early funding deals with firms like Dow Chemical and a successful 2013 IPO.[[1]](https://www.biocom.org/people/bassil-dahiyat-phd/)[[2]](https://www.lifescienceleader.com/doc/bassil-dahiyat-s-two-decade-biotech-startup-odyssey-0001)

View full insider profile →

Trade Price

$11.90

Quantity

6,758

Total Value

$80,387.00

Shares Owned

567,792

Trade Date

Tuesday, March 3, 2026

2 days ago

SEC Filing Date

Wednesday, March 4, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Xencor Inc

Company Overview

No company information available
View news mentioning XNCR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4500553

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime